Leerink Partners analyst Jonathan Chang maintained a Hold rating on Immunogen on Monday, setting a price target of $6, which is approximately 8.54% below the present share price of $6.56.
Chang expects Immunogen to post earnings per share (EPS) of -$0.17 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in ImmunoGen (NASDAQ:IMGN), with an average price target of $9.13.
The analysts price targets range from a high of $12 to a low of $6.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $15.71 million and a net profit of -$28.92 million. The company's market cap is $1.31 billion.
According to TipRanks.com, Leerink Partners analyst Jonathan Chang is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 21.1% and a 44.59% success rate.
ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.